肝癌细胞膜受体含pRSVB7特异性配基的构建  

Preparation of the unique ligand to receptor of hepatic carcinoma cells

作　　者：聂咏梅[1] 杨洁[1] 罗超权[1] 杨英浩[1] 伍新尧[1] 

机构地区：[1]中山医科大学生物化学教研室,广东省广州市510089

出　　处：《世界华人消化杂志》2000年第1期63-65,共3页World Chinese Journal of Digestology

基　　金：高等学校博士学科点专项科研基金

摘　　要：目的针对肝癌细胞HLA-B7基因的表达缺陷和具有细胞特异性的去唾液酸α1酸性糖蛋白受体的特点,构建了含HLA-B7基因的该特异性受体的配基,为肝癌的基因治疗准备了物质条件。方法以多聚(L)赖氨酸为联接桥,用碳二亚胺交联法合成去唾液酸α1酸性糖蛋白-多聚(L)赖氨酸-HLA-B7真核表达质粒复合物。结果经电泳鉴定,产物的分子量和电泳行为与预期的一致。结论本文所用的方法可行,能获得预期的产物。AIM To prepare the special ligand carrying HLA-B7 genefor hepatic carcinoma gene therapy due to failure of HLA-B7 expression and presence of unique receptor-asialoorosomucoid alpha 1 glycoprotein receptor (ASGPR)on hepatic carcinoma cells membrane.METHODS The asialoorosomucoid-poly-L-lysine-pRSVB7complex was obtained by covalently conjugating theasialoglycoprotein to poly-L-lysine which could bind theplasmid (pRSVB7) containing HLA-B7 gene. This complexis a soluble DNA carrier system which will be absorbed byhepatic carcinoma cells in vivo via ASGPR.RESULTS Electrophoresis analysis of the complexyielded the results that we had expected.CONCLUSION It was demonstrated that this method isfeasible for preparation of the ligand.

关 键 词：肝肿瘤 受体配基 基因治疗 

分 类 号：R735.7[医药卫生—肿瘤]